HRTX Q4 2022 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HRTXHeron Therapeutics, Inc.

$162M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$30M+45.4% YoY

Gross Profit

$17M57.9% margin

Operating Income

-$20M-67.8% margin

Net Income

-$20M-66.2% margin

EPS (Diluted)

$-0.23

QoQ Revenue Growth

+13.1%

Cash Flow

Operating Cash Flow

-$38M

Free Cash Flow

-$38M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$251M

Total Liabilities

$237M

Stockholders' Equity

$14M

Cash & Equivalents

$15M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$30M	$21M	+45.4%
Gross Profit	$17M	$10M	+79.1%
Operating Income	-$20M	-$54M	+62.0%
Net Income	-$20M	-$55M	+63.6%

Revenue Segments

C I N V A N T I

$23M77%

Z Y N R E L E F

$4M13%

S U S T O L

$3M10%